Kim Lewis, Ph.D.
Northeastern University
Dr. Kim Lewis is a university distinguished professor and director of the Antimicrobial Discovery Center at Northeastern University in Boston. He is a fellow of the American Academy of °®¶¹´«Ã½ and of the American Association for the Advancement of Science. He is a Highly Cited Researcher (Clarivate Analytics) and an Expertscape World Expert in microbial drug resistance (top 0.1% of scholars in the field). He obtained his Ph.D. in biochemistry from Moscow University in 1980 and has been on the faculty of MIT, University of Maryland and Tufts University prior to coming to Northeastern.
Lewis has authored over 100 papers and is an inventor on several patents. He contributed to the development of general methods to grow previously uncultured bacteria, the discovery of the culprit of recalcitrant biofilm infections, drug-tolerant persister cells and discovery of several novel antibiotics.
Lewis has served as a panelist and contributor to reports on antimicrobial resistance by National Academies Institute of Medicine, the Pew Charitable Trust and the European Academies of Science. Lewis is a member of Faculty 1000, a world-wide panel of experts evaluating research advancements. He is a recipient of the MIT C.E. Reed Faculty Initiative Award and is a recipient of the NIH Director’s Transformative Award.
Apart from his work in academia, Lewis has served as a consultant to the pharmaceutical industry, biotechnology field and is a co-founder of NovoBiotic Pharmaceuticals, Arietis Pharma, Holobiome, Flightpath and Odyssey Therapeutics.
Lewis has authored over 100 papers and is an inventor on several patents. He contributed to the development of general methods to grow previously uncultured bacteria, the discovery of the culprit of recalcitrant biofilm infections, drug-tolerant persister cells and discovery of several novel antibiotics.
Lewis has served as a panelist and contributor to reports on antimicrobial resistance by National Academies Institute of Medicine, the Pew Charitable Trust and the European Academies of Science. Lewis is a member of Faculty 1000, a world-wide panel of experts evaluating research advancements. He is a recipient of the MIT C.E. Reed Faculty Initiative Award and is a recipient of the NIH Director’s Transformative Award.
Apart from his work in academia, Lewis has served as a consultant to the pharmaceutical industry, biotechnology field and is a co-founder of NovoBiotic Pharmaceuticals, Arietis Pharma, Holobiome, Flightpath and Odyssey Therapeutics.